Simulations Plus, Inc. (NASDAQ:SLP) Director Lisa Lavange Sells 500 Shares

Simulations Plus, Inc. (NASDAQ:SLP - Get Free Report) Director Lisa Lavange sold 500 shares of the company's stock in a transaction dated Tuesday, May 14th. The shares were sold at an average price of $50.00, for a total value of $25,000.00. Following the completion of the sale, the director now owns 7,373 shares in the company, valued at approximately $368,650. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Simulations Plus Stock Up 1.6 %

Simulations Plus stock traded up $0.79 during mid-day trading on Wednesday, hitting $50.25. 76,374 shares of the stock were exchanged, compared to its average volume of 104,906. The stock has a market capitalization of $1.00 billion, a price-to-earnings ratio of 94.81 and a beta of 0.68. Simulations Plus, Inc. has a 12 month low of $32.69 and a 12 month high of $52.69. The firm's fifty day simple moving average is $45.08 and its two-hundred day simple moving average is $41.79.

Simulations Plus (NASDAQ:SLP - Get Free Report) last issued its quarterly earnings results on Wednesday, April 3rd. The technology company reported $0.20 EPS for the quarter, beating analysts' consensus estimates of $0.18 by $0.02. Simulations Plus had a net margin of 16.22% and a return on equity of 7.95%. The business had revenue of $18.31 million for the quarter, compared to analysts' expectations of $17.31 million. During the same quarter in the prior year, the firm posted $0.20 earnings per share. The business's quarterly revenue was up 16.2% compared to the same quarter last year. As a group, analysts forecast that Simulations Plus, Inc. will post 0.67 earnings per share for the current fiscal year.

Simulations Plus Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, May 6th. Shareholders of record on Monday, April 29th were issued a dividend of $0.06 per share. This represents a $0.24 dividend on an annualized basis and a dividend yield of 0.48%. The ex-dividend date was Friday, April 26th. Simulations Plus's payout ratio is 45.28%.

Institutional Trading of Simulations Plus

Several large investors have recently modified their holdings of SLP. Illinois Municipal Retirement Fund grew its stake in Simulations Plus by 2.8% in the fourth quarter. Illinois Municipal Retirement Fund now owns 9,647 shares of the technology company's stock valued at $432,000 after acquiring an additional 263 shares during the period. Price T Rowe Associates Inc. MD increased its stake in Simulations Plus by 5.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 10,048 shares of the technology company's stock valued at $414,000 after purchasing an additional 562 shares in the last quarter. Kayne Anderson Rudnick Investment Management LLC raised its holdings in Simulations Plus by 194.5% during the third quarter. Kayne Anderson Rudnick Investment Management LLC now owns 1,487 shares of the technology company's stock worth $62,000 after buying an additional 982 shares during the last quarter. Canton Hathaway LLC increased its position in shares of Simulations Plus by 25.0% during the fourth quarter. Canton Hathaway LLC now owns 5,000 shares of the technology company's stock worth $224,000 after acquiring an additional 1,000 shares in the last quarter. Finally, Campbell & CO Investment Adviser LLC raised its holdings in shares of Simulations Plus by 21.7% in the 3rd quarter. Campbell & CO Investment Adviser LLC now owns 6,089 shares of the technology company's stock worth $254,000 after acquiring an additional 1,084 shares during the last quarter. Institutional investors and hedge funds own 78.08% of the company's stock.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.